ChemicalBook CAS DataBase List 1339960-28-9

1339960-28-9

Name	Platinate(2-), [(1R,2R)-1,2-cyclohexanediamine-κN1,κN2][diphosphato(4-)-κO,κO'']-, hydrogen (1:2), (SP-4-2)-
CAS	1339960-28-9
Molecular Formula	C6H13N2O7P2Pt-
Molecular Weight	482.21
MOL File	1339960-28-9.mol

Chemical Properties

storage temp.	Store at -20°C
form	Solid
color	White to off-white

Hazard Information

Uses

Imifoplatin (PT-112) is a platinum-based active molecule and a member of the phosphaplatins family. Imifoplatin can induce Apoptosis and exhibits antitumor activity[1][2][3].

in vivo

Imifoplatin (90 mg/kg, i.v., once weekly for 5 weeks) demonstrates potent antitumor immune effects in the CT26 xenograft model^[2]. Imifoplatin (90 mg/kg, i.v., once weekly for 7 weeks) shows synergistic antitumor effects in the MC38 xenograft model, especially with PD-1 blockade (Avelumab (HY-108730))^[2].

Animal Model:	MC38 colorectal carcinoma xenograft model in C57BL/6J mice^[2]
Dosage:	90 mg/kg
Administration:	Intravenous injection (i.v.), once weekly for 7 weeks
Result:	Inhibited tumor growth, extended survival; further enhanced survival when combined with PD-1 blockade (Avelumab (HY-108730)).

Animal Model:	CT26 colorectal carcinoma xenograft model in BALB/c mice^[2]
Dosage:	90 mg/kg
Administration:	Intravenous injection (i.v.), once weekly for 5 weeks
Result:	Significantly inhibited tumor growth, increased T-cell infiltration, reduced immunosuppressive TAMs.

storage

Store at -20°C

References

[1] Moghaddas S, et, al. Phosphaplatins, next generation platinum antitumor agents: A paradigm shift in designing and defining molecular targets. Inorganica Chimica Acta. 2012 Dec; 393(1): 173-181.
[2] Yamazaki T, et al. PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models. Oncoimmunology. 2020 Feb 11;9(1):1721810. DOI:10.1080/2162402X.2020.1721810
[3] Soler-Agesta R, et al. PT-112 induces mitochondrial stress and immunogenic cell death, targeting tumor cells with mitochondrial deficiencies[J]. Cancers, 2022, 14(16): 3851. DOI:10.3390/cancers14163851

Supplier

Send Inquriy